Quarterly ResultAug 6, 2026, 07:52 AM
Novavax Q2 Revenue Plunges 76% to $56.7M; Reports $53.4M Net Loss
AI Summary
Novavax reported a significant decline in its second-quarter 2026 financial results, with revenue dropping 76% year-over-year to $56.7 million and a net loss of $53.4 million, compared to a net income in the prior year. For the first six months of 2026, the company recorded a net loss of $62.9 million on revenue of $196.2 million, down 78% from the previous year. The company continues to navigate strategic partnerships, including the Sanofi collaboration and the Gavi settlement, while facing challenges with its Australia APA.
Key Highlights
- Q2 2026 total revenue decreased 76.3% to $56.7 million from $239.2 million in Q2 2025.
- Q2 2026 net loss was $53.4 million, compared to a net income of $106.5 million in Q2 2025.
- H1 2026 total revenue decreased 78.3% to $196.2 million from $905.9 million in H1 2025.
- H1 2026 net loss was $62.9 million, compared to a net income of $625.2 million in H1 2025.
- Cash, cash equivalents, and marketable securities totaled $723.9 million as of June 30, 2026.
- Net cash used in operating activities was $105.2 million for the six months ended June 30, 2026.
- Sanofi CLA includes potential milestones up to $350 million for COVID-19 products and $350 million for CIC products.
- Gavi Settlement Agreement involves $400 million in deferred payments and up to $225 million in additional vaccine credits.
Price Impact
More from NVAX